share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Presents Overview Of DiversitAb Platform And Data Showing Benefits Of Fully-Human Polyclonal Antibodies Derived From Cows Vs. Human-Derived Plasma At 2022 Plasma Product Biotechnology Conference

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Presents Overview Of DiversitAb Platform And Data Showing Benefits Of Fully-Human Polyclonal Antibodies Derived From Cows Vs. Human-Derived Plasma At 2022 Plasma Product Biotechnology Conference

獨家報道:SAB生物治療公司告訴Benzinga Co.介紹了DiversitAb平臺的概述和數據顯示了從奶牛VS中提取的全人多克隆抗體的好處。2022年血漿產品生物技術大會上的人源性血漿
Benzinga Real-time News ·  2022/11/03 08:41

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Presents Overview Of DiversitAb Platform And Data Showing Benefits Of Fully-Human Polyclonal Antibodies Derived From Cows vs. Human-Derived Plasma At 2022 Plasma Product Biotechnology Conference

獨家報道:SAB BioTreateutics告訴Benzinga Co.在2022年血漿產品生物技術會議上,介紹了DiversitAb平臺的概述和數據,展示了牛源全人多克隆抗體與人源血漿的好處

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論